project id: TCGA-UCEC; case submitter id: TCGA-AX-A3G7; source center: 23; state: released; a260 a280 ratio: 0.35; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.6; rna integrity number: 7.4; age at index: 71; days to birth: -26187; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1939; age at diagnosis: 26187; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 9.0; figo stage: Stage IVB; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; weight: 10.0; composition: Not Reported; days to collection: 520; initial weight: 50.0; oct embedded: false; preservation method: Unknown; sample id: b44fab01-7ae7-4628-aea8-0be35ea93180; sample submitter id: TCGA-AX-A3G7-01A; portion id: 9c3978be-6075-4408-a30a-98f2500d7fe4; portion submitter id: TCGA-AX-A3G7-01A-12; slide id: 2be00a94-4771-4979-ba22-13865aa93c6a; slide submitter id: TCGA-AX-A3G7-01A-01-TS1; percent lymphocyte infiltration: 6.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 6.0; percent tumor cells: 89.0; percent tumor nuclei: 90.0; section location: TOP;